Oncology

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.

Denosumab-bbdz (Wyost; Sandoz) and denosumab-bbdz (Jubbonti; Sandoz) are approved as interchangeable for all indications of denosumab (Xgeva and Prolia; Amgen).

The next-generation SRI was previously granted an Orphan Drug Designation in November 2023 and its safety and efficacy are currently being evaluated in clinical trials.

The novel therapy is also being evaluated for the treatment of solid tumors in pancreatic and non-small cell lung cancers.

Study findings could provide scientists more knowledge on why some populations face a higher risk of lung cancer compared to others.

The FDA also granted traditional approval to amivantamab-vmjw for adults whose disease has progressed on or after platinum-based chemotherapy.

Although regulation takes time, real safety concerns for patients in the rapid development of AI technology in health care are present today.

Although cancer death rates have decreased in the United States overall, they continue to rise in rural Appalachia, engendering a malaise of fatalism in the region.

Will Shapiro, vice president of Data Science at Flatiron Health, provides context into the terminology and history of these models.

The findings suggest that the CAR T-cell membrane-coated PLGA nanoparticles reduced tumor size after 1 dose of treatment.

The authors found that overall survival in patients with newly diagnosed multiple myeloma was longest for those receiving first-line autologous stem cell transplantation.

NVL-520 is a novel brain-penetrant ROS1-selective TKI being investigated for ROS1-positive metastatic non–small cell lung cancer in patients who have previously been treated with 2 or more ROS1 TKIs.

If approved, epcoritamab (DuoBody CD3xCD20; AbbVie, Genmab) would be the first and only subcutaneous bispecific antibody for treatment in this patient population.

For more than 30 years, there has been little treatment advancement for NMIBC patients. Fortunately, a new development in the treatment of NMIBC has been approved by the FDA and is now available.

The ACCC 50th Annual Meeting & Cancer Center Business Summit is taking place in Washington, DC from February 28 to March 1.

The sNDA was based on results from the KRYSTAL-1 study, evaluating the drug alone or in combination with other anti-cancer therapies in those with advanced solid tumors who have KRASG12C mutations.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

As of January 2024, Keytruda has been approved for 6 indications in NSCLC across the metastatic and earlier stages of the disease.

The model implemented at City of Hope Chicago has been shown to improve provider workloads and enrich pharmacists’ work.

Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.

Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.

Precision oncology represents an evolution in therapeutic practice.

Currently, ocifisertib is being evaluated in a phase 1b and 2 trial to confirm the safety and tolerability profiles in patients with acute myeloid leukemia.

Teclistamab was previously approved in October 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

BAT1706 was clinically equivalent to the reference bevacizumab for efficacy, safety, pharmacokinetics, and immunogenicity.

Smoking 20 cigarettes per day significantly increased risk of death caused by certain types of melanomas.

These combination therapies have demonstrated longer PFS with a tolerable AE profile.

Datopotamab deruxtecan is an investigational TROP2 directed antibody drug conjugate that showed positive survival impact compared to chemotherapy.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.